Product

Company

Clareo Health | TNFalfa Blocking Treatment of Spondylarthropathies

NCT00133315·9 sites·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Hvidovre University Hospital

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Age\>18 years old
Spondylarthropathies according to the European Spondylarthropathy Study Group (ESSG) criteria
Sacroiliitis by X-ray or magnetic resonance imaging (MRI)
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)\>3
No signs of tuberculosis (TB)
Sufficient contraception

Wish of pregnancy or nursing
Previous treatment with TNFalfa blocker
Disease-modifying anti-rheumatic drugs (DMARDs) other than methotrexate (MTX) later than 4 weeks before inclusion
Steroid treatment later than 4 weeks before inclusion
Immunosuppressing agents later than 4 weeks before inclusion
Severe infections within 3 months
HIV-infection
Active hepatitis B and C
Active or latent TB
Severe chronic diseases
Heart insufficiency (New York Heart Association \[NYHA\] 3 and 4)
Malignancy
Systemic lupus erythematosus (SLE) or SLE-like disease
Abuse of narcotics or alcohol
Major psychiatric disorders

The record

StatusCompleted

PhasePhase 4

Taking part50

StartedSep 2004

UpdatedApr 10, 2007

Conditions

Where9